Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.69 Bil Enterprise Value: 14.74 Bil PE Ratio: 72.28 PB Ratio: 2.89 GF Score: 71/100

Biomarin Pharmaceutical Inc at SVB Leerink Global Healthcare Conference (Virtual) Transcript

Feb 26, 2021 / 04:20PM GMT
Release Date Price: $83.1
Joseph Patrick Schwartz
SVB Leerink LLC, Research Division - MD of Rare Diseases & Senior Research Analyst

Hello. Welcome to this fireside chat with BioMarin Pharmaceutical. I'm Joe Schwartz from the SVB Leerink Equity Research team. It's my pleasure to host management. Today, we're very pleased to have J.J. Bienaime, Chairman and CEO; Hank Fuchs, CMO; Brian Mueller, CFO. Welcome, gentlemen. Thanks for joining us.

Maybe we can start, J.J., by just having you give us a quick update on all of your activities and the news flow that investors should be on the lookout for this year.

Jean;Jacques Bienaime
BioMarin Pharmaceutical Inc. - Chairman & CEO

So as you know, we reported our Q4 yesterday, and I would say that the essential nature of our medicine resulted in strong growth despite, as you know, the global pandemic and the delay in ROCTAVIAN approval. As you're excluding Kuvan, BioMarin revenues grew 13% in 2020 and generated $85 million of positive operating cash flow. The '20 -- we gave guidance for '21. Our revenues are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot